Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

Abstract

Antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs) are modular targeted therapeutics in which molecular recognition is coupled with controlled payload delivery. Owing to their high specificity and precision, they have been regarded as a transformative paradigm for cancer therapy. In this review, current understandings and future perspectives of ADCs and PDCs are synthesized across rational design principles, historical evolution, clinical translation, and emerging formats, aiming to improve practical comprehension and application in oncology. Key determinants of performance: target selection, antibody or peptide carrier attributes, linker stability and cleavage mechanisms, payload classes, and conjugation strategies, are additionally discussed. Milestone advances achieved spanning hematologic malignancies and solid tumors are emphatically summarized to provide a framework by which future conjugate development may be contextualized. In parallel, the expansion of PDCs as complementary platforms is outlined, and advantages are highlighted, while limitations are also considered. ADCs and PDCs still face challenges such as toxicity, resistance, and poor stability. However, through breakthroughs including linker optimization, novel payloads, bispecific designs, and AI-driven approaches, future conjugated drugs will continue to evolve toward personalization, combination therapies, and broader indications. This article provides a systematic synthesis of extant research, thereby facilitating the future advancement of targeted conjugate drugs toward greater precision and individualization. It holds significant academic value as a reference resource and offers practical guidance for the development of novel antineoplastic therapeutics.

Keywords

antibody–drug conjugate / cancer / peptide–drug conjugate

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74 (2024): 229–263.

[2] K. S. Saini and C. Twelves, “Determining Lines of Therapy in Patients With Solid Cancers: A Proposed New Systematic and Comprehensive Framework,” British Journal of Cancer 125 (2021): 155–163.

[3] S. B. Dharap, P. Barbaniya, and S. Navgale, “Incidence and Risk Factors of Postoperative Complications in General Surgery Patients,” Cureus 14 (2022): e30975.

[4] S.-B. Kwak, S. J. Kim, J. Kim, et al., “Tumor Regionalization After Surgery: Roles of the Tumor Microenvironment and Neutrophil Extracellular Traps,” Experimental & Molecular Medicine 54 (2022): 720–729.

[5] A. Zafar, S. Khatoon, M. J. Khan, et al., “Advancements and Limitations in Traditional Anti-cancer Therapies: A Comprehensive Review of Surgery, Chemotherapy, Radiation Therapy, and Hormonal Therapy,” Discover Oncology 16 (2025): 607.

[6] V. Schirrmacher, “From Chemotherapy to Biological Therapy: A Review of Novel Concepts to Reduce the Side Effects of Systemic Cancer Treatment (review),” International Journal of Oncology 54 (2019): 407–419.

[7] U. Anand, A. Dey, A. K. S. Chandel, et al., “Cancer Chemotherapy and Beyond: Current Status, Drug Candidates, Associated Risks and Progress in Targeted Therapeutics,” Genes & Diseases 10 (2023): 1367–1401.

[8] H. Miao, Y. Fang, C. Pan, et al., “Transforming the Landscape of Cancer Treatment With Seven Promising Novel Therapies: Evolution and Future Perspectives,” Medicine Plus 2 (2025): 100087.

[9] R. Ghemrawi, L. Abuamer, S. Kremesh, et al., “Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy,” Biomedicines 12 (2024): 2158.

[10] Rituraj, R. S. Pal, J. Wahlang, et al., “Precision Oncology: Transforming Cancer Care Through Personalized Medicine,” Medical Oncology 42 (2025): 246.

[11] Y.-S. Zhu, K. Tang, and J. Lv, “Peptide-drug Conjugate-based Novel Molecular Drug Delivery System in Cancer,” Trends in Pharmacological Sciences 42 (2021): 857–869.

[12] K. B. Hong and H. An, “Degrader-antibody Conjugates: Emerging New Modality,” Journal of Medicinal Chemistry 66 (2023): 140–148.

[13] A. Thomas, B. A. Teicher, and R. Hassan, “Antibody-drug Conjugates for Cancer Therapy,” The Lancet Oncology 17 (2016): e254–e262.

[14] Z. Fu, S. Li, S. Han, et al., “Antibody Drug Conjugate: The “Biological Missile” for Targeted Cancer Therapy,” Signal Transduction and Targeted Therapy 7 (2022): 93.

[15] P. Tarantino, R. Carmagnani Pestana, C. Corti, et al., “Antibody-drug Conjugates: Smart Chemotherapy Delivery Across Tumor Histologies,” CA: A Cancer Journal for Clinicians 72 (2022): 165–182.

[16] K. Strebhardt and A. Ullrich, “Paul Ehrlich's Magic Bullet Concept: 100 Years of Progress,” Nature Reviews Cancer 8 (2008): 473–480.

[17] E. L. Sievers, R. A. Larson, E. A. Stadtmauer, et al., “Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-positive Acute Myeloid Leukemia in First Relapse,” Journal of Clinical Oncology 19 (2001): 3244–3254.

[18] W. Sun, S. Hu, and X. Wang, “Update of Antibody-drug Conjugates for Hematological Malignancies,” Current Opinion in Oncology 36 (2024): 430–436.

[19] N. Li, L. Yang, Z. Zhao, et al., “Antibody-drug Conjugates in Breast Cancer: Current Evidence and Future Directions,” Experimental Hematology & Oncology 14 (2025): 41.

[20] J. Yu, S. Wu, R. Li, et al., “Novel ADCs and Combination Therapy in Urothelial Carcinoma: Latest Updates From the 2023 ASCO-GU Cancers Symposium,” Journal of Hematology & Oncology 16 (2023): 85.

[21] X. Chen and C. Zhou, “Antibody-drug Conjugates in Lung Cancer: Current Landscape and Future Perspectives,” Current Opinion in Oncology 38 (2025): 71–82.

[22] I. Rusiecka, I. Gągało, and I. Kocić, “Cell-penetrating Peptides Improve Pharmacokinetics and Pharmacodynamics of Anticancer Drugs,” Tissue Barriers 10 (2022): 1965418.

[23] D. Pooja, A. Gunukula, N. Gupta, et al., “Bombesin Receptors as Potential Targets for Anticancer Drug Delivery and Imaging,” International Journal of Biochemistry & Cell Biology 114 (2019): 105567.

[24] Y. Wang, A. G. Cheetham, G. Angacian, et al., “Peptide-drug Conjugates as Effective Prodrug Strategies for Targeted Delivery,” Advanced Drug Delivery Reviews 110–111 (2017): 112–126.

[25] H. Jin, P. Yang, H. Min, et al., “Peptide-drug Conjugates in Tumor Therapy: Current Advances and Future Perspectives,” Cancer Letters 638 (2026): 218174.

[26] B. M. Cooper, J. Iegre, D. H. O Donovan, et al., “Peptides as a Platform for Targeted Therapeutics for Cancer: Peptide-drug Conjugates (PDCs),” Chemical Society Reviews 50 (2021): 1480–1494.

[27] X. Lai, J. Tang, and E. Meh, “Recent Advances in Proteolytic Stability for Peptide, Protein, and Antibody Drug Discovery,” Expert Opinion on Drug Discovery 16 (2021): 1467–1482.

[28] G. Mathe, L. O. C. Tran Ba, and J. Bernard, “[effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gamma-globulins From hamsters inoculated With such leukemia by heterografts],” Comptes Rendus Hebdomadaires des Seances De L Academie Des Sciences 246 (1958): 1626–1628.

[29] J. M. Sasso, R. Tenchov, R. Bird, et al., “The Evolving Landscape of Antibody-drug Conjugates: In Depth Analysis of Recent Research Progress,” Bioconjugate Chemistry 34 (2023): 1951–2000.

[30] G. Köhler and C. Milstein, “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature 256 (1975): 495–497.

[31] A. R. Mitchell, “Studies in Solid-phase Peptide Synthesis: A Personal Perspective,” Biopolymers 90 (2008): 215–233.

[32] C. de Duve, “Remembering bruce merrifield,” Biopolymers 90 (2008): 241.

[33] C. H. Ford, C. E. Newman, J. R. Johnson, et al., “Localisation and Toxicity Study of a Vindesine-anti-CEA Conjugate in Patients With Advanced Cancer,” British Journal of Cancer 47 (1983): 35–42.

[34] J. T. W. Tong, P. W. R. Harris, M. A. Brimble, et al., “An Insight Into FDA Approved Antibody-drug Conjugates for Cancer Therapy,” Molecules 26 (2021): 5847.

[35] S. A. Hurvitz, “Recent Progress in Antibody-drug Conjugate Therapy for Cancer,” Nature Cancer 3 (2022): 1412–1413.

[36] J. He, X. Zeng, C. Wang, et al., “Antibody-drug Conjugates in Cancer Therapy: Mechanisms and Clinical Studies,” MedComm 5 (2024): e671.

[37] R. Sheyi, B. G. de la Torre, and F. Albericio, “Linkers: An Assurance for Controlled Delivery of Antibody-drug Conjugate,” Pharmaceutics 14 (2022): 396.

[38] P. A. Todd and R. N. Brogden, “Muromonab CD3. A Review of Its Pharmacology and Therapeutic Potential,” Drugs 37 (1989): 871–899.

[39] B. Kelley, “The History and Potential Future of Monoclonal Antibody Therapeutics Development and Manufacturing in Four Eras,” MAbs 16 (2024): 2373330.

[40] R. Kunert and D. Reinhart, “Advances in Recombinant Antibody Manufacturing,” Applied Microbiology and Biotechnology 100 (2016): 3451–3461.

[41] M. Bestagno, M. Occhino, M. V. Corrias, et al., “Recombinant Antibodies in the Immunotherapy of Neuroblastoma: Perspectives of New Developments,” Cancer Letters 197 (2003): 193–198.

[42] P. Bruhns and F. Jönsson, “Mouse and human FcR Effector Functions,” Immunological Reviews 268 (2015): 25–51.

[43] C. S. Abrams and D. B. Cines, “Thrombocytopenia After Treatment With Platelet Glycoprotein IIb/IIIa Inhibitors,” Current Hematology Reports 3 (2004): 143–147.

[44] A. J. Grillo-López, C. A. White, B. K. Dallaire, et al., “Rituximab: The First Monoclonal Antibody Approved for the Treatment of Lymphoma,” Current Pharmaceutical Biotechnology 1 (2000): 1–9.

[45] S. De Munter, J. Ingels, G. Goetgeluk, et al., “Nanobody Based Dual Specific CARs,” International Journal of Molecular Sciences 19 (2018): 403.

[46] S. E. Sedykh, V. V. Prinz, V. N. Buneva, et al., “Bispecific Antibodies: Design, Therapy, Perspectives,” Drug Design, Development and Therapy 12 (2018): 195–208.

[47] S. Crunkhorn, “Multi-TACs Target Solid Tumours,” Nature Reviews Drug Discovery 24 (2025): 17.

[48] D. Huang, Y. Li, W. Rui, et al., “TCR-mimicking STAR Conveys Superior Sensitivity Over CAR in Targeting Tumors With Low-density Neoantigens,” Cell Reports 43 (2024): 114949.

[49] F. A. Harding, M. M. Stickler, J. Razo, et al., “The Immunogenicity of Humanized and Fully human Antibodies: Residual Immunogenicity Resides in the CDR Regions,” MAbs 2 (2010): 256–265.

[50] M. Yamashita, Y. Katakura, and S. Shirahata, “Recent Advances in the Generation of human Monoclonal Antibody,” Cytotechnology 55 (2007): 55–60.

[51] P. T. Jones, P. H. Dear, J. Foote, et al., “Replacing the Complementarity-determining Regions in a human Antibody With Those From a Mouse,” Nature 321 (1986): 522–525.

[52] R.-M. Lu, Y.-C. Hwang, I.-J. Liu, et al., “Development of Therapeutic Antibodies for the Treatment of Diseases,” Journal of Biomedical Science 27 (2020): 1.

[53] Y. Zhang, “Evolution of Phage Display Libraries for Therapeutic Antibody Discovery,” MAbs 15 (2023): 2213793.

[54] N. Lonberg, L. D. Taylor, F. A. Harding, et al., “Antigen-specific human Antibodies From Mice Comprising Four Distinct Genetic Modifications,” Nature 368 (1994): 856–859.

[55] A. Frenzel, T. Schirrmann, and M. Hust, “Phage Display-derived human Antibodies in Clinical Development and Therapy,” MAbs 8 (2016): 1177–1194.

[56] X. Lu, R. Hu, L. Peng, et al., “Efficacy and Safety of adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis,” Frontiers in Immunology 12 (2021): 638444.

[57] J. D. Bargh, A. Isidro-Llobet, J. S. Parker, et al., “Cleavable Linkers in Antibody-drug Conjugates,” Chemical Society Reviews 48 (2019): 4361–4374.

[58] H. L. Perez, P. M. Cardarelli, S. Deshpande, et al., “Antibody-drug Conjugates: Current Status and Future Directions,” Drug Discovery Today 19 (2014): 869–881.

[59] S. Zhao, N. Yu, H. Han, et al., “Advances in Acid-degradable and Enzyme-cleavable Linkers for Drug Delivery,” Current Opinion in Chemical Biology 84 (2025): 102552.

[60] I. Cheng-Sánchez, F. Moya-Utrera, C. Porras-Alcalá, et al., “Antibody-drug Conjugates Containing Payloads From Marine Origin,” Marine Drugs 20 (2022): 494.

[61] B. A. Teicher and R. V. J. Chari, “Antibody Conjugate Therapeutics: Challenges and Potential,” Clinical Cancer Research 17 (2011): 6389–6397.

[62] S. Zafar, M. Armaghan, K. Khan, et al., “New Insights Into the Anticancer Therapeutic Potential of maytansine and Its Derivatives,” Biomedicine & Pharmacotherapy 165 (2023): 115039.

[63] C. Dumontet and M. A. Jordan, “Microtubule-binding Agents: A Dynamic Field of Cancer Therapeutics,” Nature Reviews Drug Discovery 9 (2010): 790–803.

[64] M. Xi, J. Zhu, F. Zhang, et al., “Antibody-drug Conjugates for Targeted Cancer Therapy: Recent Advances in Potential Payloads,” European Journal of Medicinal Chemistry 276 (2024): 116709.

[65] S. Florian and T. J. Mitchison, “Anti-microtubule Drugs,” Methods in Molecular Biology 1413 (2016): 403–421.

[66] Y. Jin, M. A. Schladetsch, X. Huang, et al., “Stepping Forward in Antibody-drug Conjugate Development,” Pharmacology & Therapeutics 229 (2022): 107917.

[67] R. Wang, B. Hu, Z. Pan, et al., “Antibody-drug Conjugates (ADCs): Current and Future Biopharmaceuticals,” Journal of Hematology & Oncology 18 (2025): 51.

[68] P. Schöffski, C.-C. Wang, M. P. Schöffski, et al., “Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-specific Antibody-drug Conjugates,” Oncology Research and Treatment 47 (2024): 18–41.

[69] A. Thomas and Y. Pommier, “Targeting Topoisomerase I in the Era of Precision Medicine,” Clinical Cancer Research 25 (2019): 6581–6589.

[70] R. Misra, R. Gupta, N. Nayyar, et al., “Bacterial Protein Toxins as Anticancer Agents: Clinical Potential of pseudomonas and Anthrax Toxins,” Toxins (Basel) 17 (2025): 459.

[71] J. Sandland and R. W. Boyle, “Photosensitizer Antibody–drug Conjugates: Past, Present, and Future,” Bioconjugate Chemistry 30 (2019): 975–993.

[72] W. Dong, W. Wang, and C. Cao, “The Evolution of Antibody-drug Conjugates: Toward Accurate DAR and Multi-specificity,” Chemmedchem 19 (2024): e202400109.

[73] B. Liu, H. V.-T. Nguyen, and Y. Jiang, “Antibody-bottlebrush Prodrug Conjugates for Targeted Cancer Therapy,” Nature Biotechnology 44 (2025): 1011–1022.

[74] K. J. Hamblett, P. D. Senter, D. F. Chace, et al., “Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate,” Clinical Cancer Research 10 (2004): 7063–7070.

[75] S. J. Walsh, J. D. Bargh, F. M. Dannheim, et al., “Site-selective Modification Strategies in Antibody-drug Conjugates,” Chemical Society Reviews 50 (2021): 1305–1353.

[76] S. Panowski, S. Bhakta, H. Raab, et al., “Site-specific Antibody Drug Conjugates for Cancer Therapy,” MAbs 6 (2014): 34–45.

[77] A. Beck, J.-F. Haeuw, T. Wurch, et al., “The next Generation of Antibody-drug Conjugates Comes of Age,” Discovery Medicine 10 (2010): 329–339.

[78] L. H. Sehn, A. F. Herrera, C. R. Flowers, et al., “Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma,” Journal of Clinical Oncology 38 (2020): 155–165.

[79] G. Badescu, P. Bryant, M. Bird, et al., “Bridging Disulfides for Stable and Defined Antibody Drug Conjugates,” Bioconjugate Chemistry 25 (2014): 1124–1136.

[80] S. A. Kularatne, V. Deshmukh, J. Ma, et al., “A CXCR4-targeted Site-specific Antibody-drug Conjugate,” Angewandte Chemie 53 (2014): 11863–11867.

[81] B. C. Bundy and J. R. Swartz, “Site-specific Incorporation of p-propargyloxyphenylalanine in a Cell-free Environment for Direct Protein-protein Click Conjugation,” Bioconjugate Chemistry 21 (2010): 255–263.

[82] H. Chon, S. Kanamori, K. Hibino, et al., “ez-ADiCon: A Novel Glyco-remodeling Based Strategy That Enables Preparation of Homogenous Antibody-drug Conjugates via One-step Enzymatic Transglycosylation With Payload-preloaded bi-antennary Glycan Complexes,” Bioorganic & Medicinal Chemistry Letters 80 (2023): 129117.

[83] V. S. Shivatare, H.-W. Huang, T.-H. Tseng, et al., “Probing the Internalization and Efficacy of Antibody-Drug Conjugate via Site-Specific Fc-Glycan Labelling of a Homogeneous Antibody Targeting SSEA-4 Bearing Tumors,” Israel Journal of Chemistry 63 (2023): e202300042.

[84] M. J. Lobba, C. Fellmann, A. M. Marmelstein, et al., “Site-Specific Bioconjugation Through Enzyme-Catalyzed Tyrosine-Cysteine Bond Formation,” ACS Central Science 6 (2020): 1564–1571.

[85] P. Strop, “Versatility of Microbial Transglutaminase,” Bioconjugate Chemistry 25 (2014): 855–862.

[86] J. R. Junutula, H. Raab, S. Clark, et al., “Site-specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index,” Nature Biotechnology 26 (2008): 925–932.

[87] A. G. Polson, S.-F. Yu, K. Elkins, et al., “Antibody-drug Conjugates Targeted to CD79 for the Treatment of non-hodgkin Lymphoma,” Blood 110 (2007): 616–623.

[88] J. M. Burke, F. Morschhauser, D. Andorsky, et al., “Antibody-drug Conjugates for Previously Treated Aggressive Lymphomas: Focus on Polatuzumab vedotin,” Expert Review of Clinical Pharmacology 13 (2020): 1073–1083.

[89] S. L. Kuan, T. Wang, and T. Weil, “Site-selective Disulfide Modification of Proteins: Expanding Diversity Beyond the Proteome,” Chemistry 22 (2016): 17112–17129.

[90] F. A. Liberatore, R. D. Comeau, J. M. McKearin, et al., “Site-directed Chemical Modification and Cross-linking of a Monoclonal Antibody Using Equilibrium Transfer Alkylating Cross-link Reagents,” Bioconjugate Chemistry 1 (1990): 36–50.

[91] J. M. J. M. Ravasco, H. Faustino, A. Trindade, et al., “Bioconjugation With Maleimides: A Useful Tool for Chemical Biology,” Chemistry 25 (2019): 43–59.

[92] R. J. Christie, R. Fleming, B. Bezabeh, et al., “Stabilization of Cysteine-linked Antibody Drug Conjugates With N-aryl Maleimides,” Journal of Control Release 220 (2015): 660–670.

[93] R. P. Lyon, J. R. Setter, T. D. Bovee, et al., “Self-hydrolyzing Maleimides Improve the Stability and Pharmacological Properties of Antibody-drug Conjugates,” Nature Biotechnology 32 (2014): 1059–1062.

[94] I. Dovgan, S. Kolodych, O. Koniev, et al., “2-(maleimidomethyl)-1,3-dioxanes (MD): A Serum-stable Self-hydrolysable Hydrophilic Alternative to Classical Maleimide Conjugation,” Scientific Reports 6 (2016): 30835.

[95] D. Kalia, P. V. Malekar, and M. Parthasarathy, “Exocyclic Olefinic Maleimides: Synthesis and Application for Stable and Thiol-selective Bioconjugation,” Angewandte Chemie 55 (2016): 1432–1435.

[96] T. J. Hallam, E. Wold, A. Wahl, and V. V. Smider, “Antibody Conjugates With Unnatural Amino Acids,” Mol Pharm 12 (2015): 1848–1862.

[97] S. A. Kularatne, V. Deshmukh, J. Ma, et al., “A CXCR4-targeted Site-specific Antibody-drug Conjugate,” Angewandte Chemie (International Ed in English) 53 (2014): 11863–11867.

[98] H. Kaur, “Characterization of Glycosylation in Monoclonal Antibodies and Its Importance in Therapeutic Antibody Development,” Critical Reviews in Biotechnology 41 (2021): 300–315.

[99] T. Kline, A. R. Steiner, K. Penta, et al., “Methods to Make Homogenous Antibody Drug Conjugates,” Pharmaceutical Research 32 (2015): 3480–3493.

[100] Y. Choi, Y. Choi, and S. Hong, “Recent Technological and Intellectual Property Trends in Antibody-Drug Conjugate Research,” Pharmaceutics 16 (2024): 221.

[101] E. L. Sievers and M. Linenberger, “Mylotarg: Antibody-targeted Chemotherapy Comes of Age,” Current Opinion in Oncology 13 (2001): 522–527.

[102] J. K. McGavin and C. M. Spencer, “Gemtuzumab Ozogamicin,” Drugs 61 (2001): 1317–1322, discussion 1323–1324.

[103] J. M. Rowe and B. Löwenberg, “Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: A Remarkable Saga About an Active Drug,” Blood 121 (2013): 4838–4841.

[104] S. M. Ansell, “Brentuximab vedotin,” Blood 124 (2014): 3197–3200.

[105] A. Beck, L. Goetsch, C. Dumontet, et al., “Strategies and Challenges for the next Generation of Antibody-drug Conjugates,” Nature Reviews Drug Discovery 16 (2017): 315–337.

[106] L. Amiri-Kordestani, G. M. Blumenthal, Q. C. Xu, et al., “FDA Approval: Ado-trastuzumab emtansine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer,” Clinical Cancer Research 20 (2014): 4436–4441.

[107] S. Verma, D. Miles, L. Gianni, et al., “Trastuzumab Emtansine for HER2-positive Advanced Breast Cancer,” New England Journal of Medicine 367 (2012): 1783–1791.

[108] K. J. Norsworthy, C.-W. Ko, J. E. Lee, et al., “FDA Approval Summary: Mylotarg for Treatment of Patients With Relapsed or Refractory CD33-positive Acute Myeloid Leukemia,” The Oncologist 23 (2018): 1103–1108.

[109] A.-L. Taksin, O. Legrand, E. Raffoux, et al., “High Efficacy and Safety Profile of Fractionated Doses of mylotarg as Induction Therapy in Patients With Relapsed Acute Myeloblastic Leukemia: A Prospective Study of the alfa Group,” Leukemia 21 (2007): 66–71.

[110] S. Castaigne, C. Pautas, C. Terré, et al., “Effect of Gemtuzumab Ozogamicin on Survival of Adult Patients With De-novo Acute Myeloid Leukaemia (ALFA-0701): A Randomised, Open-label, Phase 3 Study,” Lancet 379 (2012): 1508–1516.

[111] J. Lambert, C. Pautas, C. Terré, et al., “Gemtuzumab ozogamicin for De Novo Acute Myeloid Leukemia: Final Efficacy and Safety Updates From the Open-label, Phase III ALFA-0701 Trial,” Haematologica 104 (2019): 113–119.

[112] S. Amadori, S. Suciu, D. Selleslag, et al., “Gemtuzumab Ozogamicin versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial,” Journal of Clinical Oncology 34 (2016): 972–979.

[113] C. for D.E. and Research, “FDA Approves inotuzumab ozogamicin for Relapsed or Refractory B-cell Precursor ALL,” FDA (2024).

[114] H. M. Kantarjian, D. J. DeAngelo, and M. Stelljes, “Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia,” The New England Journal of Medicine 375 (2016): 740–753.

[115] S. Dhillon, “Moxetumomab pasudotox: First Global Approval,” Drugs 78 (2018): 1763–1767.

[116] R. J. Kreitman, C. Dearden, P. L. Zinzani, et al., “Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia,” Leukemia 32 (2018): 1768–1777.

[117] R. J. Kreitman, C. Dearden, P. L. Zinzani, et al., “Moxetumomab pasudotox in Heavily Pre-treated Patients With Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-term Follow-up From the Pivotal Trial,” Journal of Hematology & Oncology 14 (2021): 35.

[118] Z. Wang, H. Li, L. Gou, et al., “Antibody–drug Conjugates: Recent Advances in Payloads,” Acta Pharmaceutica Sinica B 13 (2023): 4025–4059.

[119] V. Camus and H. Tilly, “Polatuzumab vedotin, an Anti-CD79b Antibody-drug Conjugate for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma,” Future Oncology 17 (2021): 127–135.

[120] L. H. Sehn, M. Hertzberg, S. Opat, et al., “Polatuzumab vedotin plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL: Survival Update and New Extension Cohort Data,” Blood Advances 6 (2022): 533–543.

[121] P. M. Challita-Eid, D. Satpayev, P. Yang, et al., “Enfortumab Vedotin Antibody-drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models,” Cancer Research 76 (2016): 3003–3013.

[122] M. Nikanjam, J. Pérez-Granado, M. Gramling, B. Larvol, and R. Kurzrock, “Nectin-4 Expression Patterns and Therapeutics in Oncology,” Cancer Letters 622 (2025): 217681.

[123] J. E. Rosenberg, P. H. O'Donnell, A. V. Balar, et al., “Pivotal Trial of enfortumab vedotin in Urothelial Carcinoma After Platinum and Anti-programmed Death 1/Programmed Death Ligand 1 Therapy,” Journal of Clinical Oncology 37 (2019): 2592–2600.

[124] E. Y. Yu, D. P. Petrylak, P. H. O'Donnell, et al., “Enfortumab vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma (EV-201): A Multicentre, Single-arm, Phase 2 Trial,” The Lancet Oncology 22 (2021): 872–882.

[125] Y. Ogitani, T. Aida, K. Hagihara, et al., “DS-8201a, a Novel HER2-targeting ADC With a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy With Differentiation From T-DM1,” Clinical Cancer Research 22 (2016): 5097–5108.

[126] S. Modi, C. Saura, T. Yamashita, et al., “Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer,” New England Journal of Medicine 382 (2020): 610–621.

[127] P. Narayan, C. L. Osgood, H. Singh, et al., “FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for the Treatment of Unresectable or Metastatic HER2-positive Breast Cancer,” Clinical Cancer Research 27 (2021): 4478–4485.

[128] S. Modi, W. Jacot, T. Yamashita, et al., “Trastuzumab deruxtecan in Previously Treated HER2-low Advanced Breast Cancer,” New England Journal of Medicine 387 (2022): 9–20.

[129] A. Bardia, X. Hu, R. Dent, et al., “Trastuzumab deruxtecan After Endocrine Therapy in Metastatic Breast Cancer,” New England Journal of Medicine 391 (2024): 2110–2122.

[130] K. Shitara, Y.-J. Bang, S. Iwasa, et al., “Trastuzumab deruxtecan in Previously Treated HER2-positive Gastric Cancer,” New England Journal of Medicine 382 (2020): 2419–2430.

[131] D. M. Goldenberg, T. M. Cardillo, S. V. Govindan, et al., “Trop-2 Is a Novel Target for Solid Cancer Therapy With Sacituzumab Govitecan (IMMU-132), an Antibody-drug Conjugate (ADC),” Oncotarget 6 (2015): 22496–22512.

[132] A. Bardia, W. A. Messersmith, E. A. Kio, et al., “Sacituzumab govitecan, a Trop-2-directed Antibody-drug Conjugate, for Patients With Epithelial Cancer: Final Safety and Efficacy Results From the Phase I/II IMMU-132-01 Basket Trial,” Annals of Oncology 32 (2021): 746–756.

[133] A. Bardia, H. S. Rugo, S. M. Tolaney, et al., “Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-negative Breast Cancer and Association of Outcomes by human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression,” Journal of Clinical Oncology 42 (2024): 1738–1744.

[134] S. T. Tagawa, A. V. Balar, D. P. Petrylak, et al., “TROPHY-U-01: A Phase II Open-label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-based Chemotherapy and Checkpoint Inhibitors,” Journal of Clinical Oncology 39 (2021): 2474–2485.

[135] A. A. Almodovar Diaz, S. S. Alouch, and Y. Chawla, “The Antibody Drug Conjugate, Belantamab-mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review,” Blood Lymphat Cancer 14 (2024): 71–87.

[136] S. Lonial, H. C. Lee, A. Badros, et al., “Belantamab mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-arm, Randomised, Open-label, Phase 2 Study,” The Lancet Oncology 21 (2020): 207–221.

[137] M. A. Dimopoulos, V. T. M. Hungria, A. Radinoff, et al., “Efficacy and Safety of Single-agent belantamab mafodotin versus pomalidomide plus Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (DREAMM-3): A Phase 3, Open-label, Randomised Study,” The Lancet Haematology 10 (2023): e801–e812.

[138] V. Hungria, P. Robak, M. Hus, et al., “Belantamab mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma,” New England Journal of Medicine 391 (2024): 393–407.

[139] V. Hungria, P. Robak, M. Hus, et al., “Belantamab mafodotin plus Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (DREAMM-7): Updated Overall Survival Analysis From a Global, Randomised, Open-label, Phase 3 Trial,” The Lancet Oncology 26 (2025): 1067–1080.

[140] S. Trudel, M. Beksac, L. Pour, et al., “Results From the Randomized Phase 3 DREAMM-8 Study of belantamab Mafodotin plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM),” Journal of Clinical Oncology 42 (2024): LBA105–LBA105.

[141] H. Kobayashi and P. L. Choyke, “Near-infrared Photoimmunotherapy of Cancer,” Accounts of Chemical Research 52 (2019): 2332–2339.

[142] L. C. Gomes-da-Silva, O. Kepp, and G. Kroemer, “Regulatory Approval of Photoimmunotherapy: Photodynamic Therapy That Induces Immunogenic Cell Death,” Oncoimmunology 9 (2020): 1841393.

[143] N. L. Miyazaki, A. Furusawa, P. L. Choyke, et al., “Review of RM-1929 near-infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma,” Cancers (Basel) 15 (2023): 5117.

[144] D. M. Cognetti, J. M. Johnson, J. M. Curry, et al., “Phase 1/2a, Open-label, Multicenter Study of RM-1929 Photoimmunotherapy in Patients With Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma,” Head & Neck 43 (2021): 3875–3887.

[145] A. Lee, “Loncastuximab tesirine: First Approval,” Drugs 81 (2021): 1229–1233.

[146] M. Hamadani, J. Radford, C. Carlo-Stella, et al., “Final Results of a Phase 1 Study of loncastuximab tesirine in Relapsed/Refractory B-cell Non-hodgkin Lymphoma,” Blood 137 (2021): 2634–2645.

[147] P. F. Caimi, W. Ai, J. P. Alderuccio, et al., “Loncastuximab tesirine in Relapsed or Refractory Diffuse Large B-cell Lymphoma (LOTIS-2): A Multicentre, Open-label, Single-arm, Phase 2 Trial,” The Lancet Oncology 22 (2021): 790–800.

[148] C. H. Moskowitz, M. Bastos-Oreiro, D. Ungar, et al., “Safety and Anti-tumor Activity Study of Loncastuximab tesirine and durvalumab in Diffuse Large B-cell, Mantle Cell, or Follicular Lymphoma,” Blood 134 (2019): 2807.

[149] A. Markham, “Tisotumab vedotin: First Approval,” Drugs 81 (2021): 2141–2147.

[150] J. S. de Bono, N. Concin, D. S. Hong, et al., “Tisotumab vedotin in Patients With Advanced or Metastatic Solid Tumours (InnovaTV 201): A First-in-human, Multicentre, Phase 1–2 Trial,” The Lancet Oncology 20 (2019): 383–393.

[151] R. L. Coleman, D. Lorusso, C. Gennigens, et al., “Efficacy and Safety of tisotumab vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer (innovaTV 204/GOG-3023/ENGOT-cx6): A Multicentre, Open-label, Single-arm, Phase 2 Study,” The Lancet Oncology 22 (2021): 609–619.

[152] I. Vergote, A. González-Martín, K. Fujiwara, et al., “Tisotumab vedotin as Second- or Third-line Therapy for Recurrent Cervical Cancer,” New England Journal of Medicine 391 (2024): 44–55.

[153] F. Shi, Y. Liu, X. Zhou, et al., “Disitamab vedotin: A Novel Antibody-drug Conjugates for Cancer Therapy,” Drug Delivery 29 (2022): 1335–1344.

[154] Z. Peng, T. Liu, J. Wei, et al., “Efficacy and Safety of a Novel Anti-HER2 Therapeutic Antibody RC48 in Patients With HER2-overexpressing, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer: A Single-arm Phase II Study,” Cancer Communications (London) 41 (2021): 1173–1182.

[155] E. D. Deeks, “Disitamab vedotin: First Approval,” Drugs 81 (2021): 1929–1935.

[156] Y. Ogitani, K. Hagihara, M. Oitate, et al., “Bystander Killing Effect of DS-8201a, a Novel Anti-human Epidermal Growth Factor Receptor 2 Antibody–drug Conjugate, in Tumors With human Epidermal Growth Factor Receptor 2 Heterogeneity,” Cancer Science 107 (2016): 1039–1046.

[157] O. Ab, K. R. Whiteman, L. M. Bartle, et al., “IMGN853, a Folate Receptor-α (FRα)-targeting Antibody-drug Conjugate, Exhibits Potent Targeted Antitumor Activity Against FRα-expressing Tumors,” Molecular Cancer Therapeutics 14 (2015): 1605–1613.

[158] U. A. Matulonis, D. Lorusso, A. Oaknin, et al., “Efficacy and Safety of mirvetuximab soravtansine in Patients With Platinum-resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study,” Journal of Clinical Oncology 41 (2023): 2436–2445.

[159] K. N. Moore, A. Angelergues, G. E. Konecny, et al., “Mirvetuximab soravtansine in FRα-positive, Platinum-resistant Ovarian Cancer,” New England Journal of Medicine 389 (2023): 2162–2174.

[160] H. A. Blair, “Datopotamab deruxtecan: First Approval,” Drugs 85 (2025): 965–975.

[161] A. Bardia, K. Jhaveri, S.-A. Im, et al., “Datopotamab deruxtecan versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-positive human Epidermal Growth Factor Receptor 2-negative Breast Cancer: Primary Results From TROPION-Breast01,” Journal of Clinical Oncology 43 (2025): 285–296.

[162] M.-J. Ahn, K. Tanaka, L. Paz-Ares, et al., “Datopotamab deruxtecan versus docetaxel for Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer: The Randomized, Open-label Phase III TROPION-Lung01 Study,” Journal of Clinical Oncology 43 (2025): 260–272.

[163] H. A. Blair, “Telisotuzumab vedotin: First Approval,” Drugs 85 (2025): 1171–1176.

[164] D. R. Camidge, J. Bar, H. Horinouchi, et al., “Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-met Protein-overexpressing Advanced Nonsquamous EGFR-wildtype Non-small Cell Lung Cancer in the Phase II LUMINOSITY Trial,” Journal of Clinical Oncology 42 (2024): 3000–3011.

[165] Y. Cheng, X. Yuan, Q. Tian, et al., “Preclinical Profiles of SKB264, a Novel Anti-TROP2 Antibody Conjugated to Topoisomerase Inhibitor, Demonstrated Promising Antitumor Efficacy Compared to IMMU-132,” Frontiers in Oncology 12 (2022): 951589.

[166] B. Xu, Y. Yin, Y. Fan, et al., “Sacituzumab Tirumotecan (SKB264/MK-2870) in Patients (pts) With Previously Treated Locally Recurrent or Metastatic Triple-negative Breast Cancer (TNBC): Results From the Phase III OptiTROP-Breast01 Study,” Journal of Clinical Oncology 42 (2024): 104–104.

[167] W. Fang, X. Li, Q. Wang, et al., “Sacituzumab tirumotecan versus docetaxel for Previously Treated EGFR-mutated Advanced Non-small Cell Lung Cancer: Multicentre, Open Label, Randomised Controlled Trial,” Bmj 389 (2025): e085680.

[168] W. Fang, L. Wu, X. Meng, et al., “Sacituzumab Tirumotecan in EGFR-TKI-resistant, EGFR-mutated Advanced NSCLC,” New England Journal of Medicine 394 (2025): 13–26.

[169] Z. Li, Y. Wang, Y. Sun, et al., “Trastuzumab Rezetecan, a HER2-directed Antibody-drug Conjugate, in Patients With Advanced HER2-mutant Non-small-cell Lung Cancer (HORIZON-lung): Phase 2 Results From a Multicentre, Single-arm Study,” The Lancet Oncology 26 (2025): 437–446.

[170] Y. Liu, W. Lian, X. Zhao, et al., “A First in-human Study of A166 in Patients With Locally Advanced/Metastatic Solid Tumors Which Are HER2-positive or HER2-amplified Who Did Not Respond or Stopped Responding to Approved Therapies,” Journal of Clinical Oncology 38 (2020): 1049.

[171] J. Zhang, R. Liu, S. Gao, et al., “Phase I Study of A166, an Antibody-Drug Conjugate in Advanced HER2-expressing Solid Tumours,” Npj Breast Cancer 9 (2023): 28.

[172] X. Hu, J. Zhang, Q. Ouyang, et al., “LBA24 trastuzumab Botidotin vs trastuzumab Emtansine (T-DM1) in HER2-positive Unresectable or Metastatic Breast Cancer: Results From a Randomized Phase III Study,” Annals of Oncology 36 (2025): S1684.

[173] M.-Z. Qiu, Y. Zhang, Y. Guo, et al., “Evaluation of Safety of Treatment With Anti-epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial,” JAMA Oncology 8 (2022): 1042–1046.

[174] X. Wang, Y. Xiang, L.-Q. Tang, et al., “Becotatug Vedotin vs. chemotherapy in Pre-heavily Treated Advanced Nasopharyngeal Carcinoma: A Randomized, Controlled, Multicenter, Open-label Study,” Journal of Clinical Oncology 43 (2025): LBA6005.

[175] X. Li, S. Zhou, C. L. Abrahams, et al., “Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers,” Molecular Cancer Therapeutics 22 (2023): 155–167.

[176] T. Tang, Q. Le, S. Castro, et al., “Targeting FOLR1 in High-risk CBF2AT3-GLIS2 Pediatric AML With STRO-002 FOLR1–antibody-drug Conjugate,” Blood Advances 6 (2022): 5933–5937.

[177] A. Oaknin, L. Fariñas-Madrid, C. García-Duran, et al., “Luveltamab Tazevibulin (STRO-002), an Anti-folate Receptor Alpha (FolRα) Antibody Drug Conjugate (ADC), Safety and Efficacy in a Broad Distribution of FolRα Expression in Patients With Recurrent Epithelial Ovarian Cancer (OC): Update of STRO-002-GM1 Phase 1 Dose Expansion Cohort,” Journal of Clinical Oncology 41 (2023): 5508–5508.

[178] A. Oaknin, D. Lorusso, K. Pietzner, et al., “TP010/#1537  efficacy and Safety of luveltamab tazevibulin in Patients With Recurrent Platinum-resistant Ovarian Cancer: The Reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) Phase 2/3 Study,” International Journal of Gynecological Cancer 34 (2024): A351.

[179] R. Yuan, A. McGeehan, S. Zhou, et al., “The Anti-FRα Antibody-drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non-small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death,” Molecular Cancer Therapeutics 24 (2025): 1428–1441.

[180] S. Sen, S. Sahota, L. L. Siu, et al., “TUB-030, a Novel ADC Targeting 5T4: A Phase I/IIa Multi-center, First-in-human Clinical Trial (5-STAR 1-01) in Patients With Advanced Solid Tumors,” Journal of Clinical Oncology 43 (2025): TPS3164–TPS3164.

[181] J. Zhang, Z. Z. Zhou, K. Chen, et al., “A CD276-targeted Antibody-drug Conjugate to Treat Non-small Lung Cancer (NSCLC),” Cells 12 (2023): 2393.

[182] R. Wang, P. Fang, W. Zhou, et al., “Abstract 5466: 7MW4911, a Novel Cadherin 17-targeting ADC, Demonstrates Potent Efficacy in Preclinical Models of Gastrointestinal Cancers,” Cancer Research 85 (2025): 5466.

[183] C. Wang, X. Zhang, N. Zhang, et al., “Abstract 4751: CS5005: A Novel SSTR2-targeted Antibody-drug Conjugate (ADC) With Robust Antitumor Activity in Preclinical Studies,” Cancer Research 85 (2025): 4751.

[184] B. Kwan, M. Ramirez, S. Jin, et al., “783 SGN-PDL1V, a Novel, Investigational PD-L1-directed Antibody-drug Conjugate for the Treatment of Solid Tumors,” Journal for ImmunoTherapy of Cancer 9 (2021): A818–A818.

[185] Y. Shan, R. Liu, G. Song, et al., “693P preclinical Activity of HLX43, a PD-L1-targeting ADC, in Multiple PD-1/PD-L1 Refractory/Resistant Models,” Annals of Oncology 34 (2023): S483.

[186] J. Wang, R. Wan, S. Zeng, et al., “PT2.10.03 safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study,” Journal of Thoracic Oncology 20 (2025): S608.

[187] Y. Huang, L. Chen, F. Wang, et al., “A Dose Escalation and Cohort Expansion Phase I/IIa Study of ACR246, an Innovative 5T4- antibody Drug Conjugate (ADC), in Patients (pts) With Advanced Solid Tumors,” Journal of Clinical Oncology 43 (2025): TPS3166.

[188] J. McNally, B. Bezabeh, J. Dong, et al., “Abstract 5447: Development and Preclinical Evaluation of JK06, a Biparatopic ADC Against 5T4,” Cancer Research 85 (2025): 5447.

[189] X. Ding, C.-S. Tsai, M.-H. Tsai, et al., “Abstract 5731: BGB-C354, a Novel B7H3 ADC With High DAR Stability and Strong Bystander Effect, Demonstrates Robust Antitumor Activity in Preclinical Models,” Cancer Research 85 (2025): 5731.

[190] J. A. Scribner, J. G. Brown, T. Son, et al., “Abstract 1904: Preclinical Development of MGC026, a Glycan-linked, Exatecan-based Antibody-drug Conjugate (ADC) Targeting B7-H3 for Solid Cancer,” Cancer Research 84 (2024): 1904.

[191] W. Lian, Q. Zong, C. Deng, et al., “Abstract 2940: Preclinical Development of a next Generation Antibody Drug Conjugate (ADC) Targeting CDH17 for Treatment of Solid Tumors,” Cancer Research 85 (2025): 2940.

[192] G. Mu, F. Zhou, Z. Zha, et al., “Abstract 2863: TAVO307, a Novel ADC Targeting CDH17, for the Therapy of Gastrointestinal Cancers,” Cancer Research 85 (2025): 2863.

[193] N. Kalynovska, D. Hudecz, M. Hrdinka, et al., “Abstract 5469: Preclinical Safety and Efficacy of SOT109, an Antibody-drug Conjugate Targeting Cadherin 17 (CDH17) for the Treatment of Colorectal and Other Gastrointestinal Tract Tumors,” Cancer Research 85 (2025): 5469.

[194] X. Zhao, J. Zhu, Y. Zhou, et al., “Abstract 1886: BRY812, an Anti-LIV-1 Antibody Drug Conjugate With Novel Conjugation Method for Cancer Therapeutics,” Cancer Research 84 (2024): 1886.

[195] Y. Gong, X. Sun, C. Yang, et al., “Abstract 3134: SDP03923-000-9106, a Novel and Optimized LIV-1 ADC With Superior Anti-tumor Efficacy in Breast Cancer Xenograft Models,” Cancer Research 84 (2024): 3134.

[196] L.-C. Tsao, J. S. Wang, X. Ma, et al., “Effective Extracellular Payload Release and Immunomodulatory Interactions Govern the Therapeutic Effect of Trastuzumab deruxtecan (T-DXd),” Nature Communications 16 (2025): 3167.

[197] S. Modi, R. Salgado, V. Guarneri, et al., “Abstract PO2-19-06: An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15,” Cancer Research 84 (2024): PO2-19-06.

[198] O. Kepp and G. Kroemer, “Immunogenic Cell Death and Bystander Killing: Expanding the Therapeutic Potential of Modern Antibody-drug Conjugates,” Oncoimmunology 14 (2025): 2533488.

[199] A. Zippelius, S. M. Tolaney, P. Tarantino, et al., “Unveiling the Molecular and Immunological Drivers of Antibody–drug Conjugates in Cancer Treatment,” Nature Reviews Cancer 25 (2025): 1–20.

[200] T. Powles, B. P. Valderrama, S. Gupta, et al., “Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer,” New England Journal of Medicine 390 (2024): 875–888.

[201] S. Gupta, Y. Loriot, M. S. Van der Heijden, et al., “Enfortumab Vedotin plus Pembrolizumab versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302): Patient-reported Outcomes From an Open-label, Randomised, Controlled, Phase 3 Study,” The Lancet Oncology 26 (2025): 795–805.

[202] S. M. Tolaney, E. de Azambuja, K. Kalinsky, et al., “Sacituzumab Govitecan (SG) + Pembrolizumab (pembro) vs Chemotherapy (chemo) + Pembro in Previously Untreated PD-L1–positive Advanced Triple-negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study,” Journal of Clinical Oncology 43 (2025): LBA109–LBA109.

[203] B. P. Levy, L. G. Paz-Ares, C.-C. Lin, et al., “TROPION-Lung02: Datopotamab Deruxtecan (dato-DXd) plus Pembrolizumab (pembro) With or Without Platinum Chemotherapy (pt-CT) as First-line (1L) Therapy for Advanced Non-small Cell Lung Cancer (aNSCLC),” Journal of Clinical Oncology 43 (2025): 8501–8501.

[204] I. Okamoto, S. Kuyama, N. Girard, et al., “TROPION-Lung07: Phase III Study of Dato-DXd + Pembrolizumab ± Platinum-based Chemotherapy as 1L Therapy for Advanced Non-small-cell Lung Cancer,” Future Oncology 20 (2024): 2927–2936.

[205] B. P. Levy, E. Felip, M. Reck, et al., “TROPION-Lung08: Phase III Study of Datopotamab Deruxtecan plus Pembrolizumab as First-line Therapy for Advanced NSCLC,” Future Oncology 19 (2023): 1461–1472.

[206] C. Aggarwal, P. Cheema, O. Arrieta, et al., “P2.04-02 AVANZAR: Phase III Study of Datopotamab Deruxtecan (dato-DXd) + Durvalumab + Carboplatin as 1L Treatment of Advanced/mNSCLC,” Journal of Thoracic Oncology 18 (2023): S305–S306.

[207] S. N. Waqar, K. Cuppens, R. G. Campelo, et al., “First-line (1L) Datopotamab deruxtecan (dato-DXd) + rilvegostomig in Advanced or Metastatic Non-small Cell Lung Cancer (a/mNSCLC): Results From TROPION-Lung04 (cohort 5),” Journal of Clinical Oncology 43 (2025): 8521–8521.

[208] T. Newsom-Davis, B. Solomon, B. Melosky, et al., “122TiP: TROPION-Lung10: Phase III Study of Datopotamab Deruxtecan (dato-DXd) + Rilvegostomig in Non-squamous (NSQ) Advanced/Metastatic (a/m) Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression and Without Actionable Genomic Alterations (AGAs),” Journal of Thoracic Oncology 20 (2025): S85–S86.

[209] W. Fang, Q. Wang, Y. Cheng, et al., “Sacituzumab Tirumotecan (sac-TMT) in Combination With tagitanlimab (anti-PD-L1) in First-line (1L) Advanced Non-small-cell Lung Cancer (NSCLC): Non-squamous Cohort From the Phase II OptiTROP-Lung01 Study,” Journal of Clinical Oncology 43 (2025): 8529–8529.

[210] S. Jiang, H. Guo, H. Qu, et al., “9MW2821, a Novel Nectin-4 Antibody-drug Conjugate (ADC), Combined With toripalimab in Treatment-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 1b/2 Study,” Journal of Clinical Oncology 43 (2025): 4519–4519.

[211] F. Wang, Z. Guo, M. J. Carr, et al., “PARPs and PARP Inhibitors: Molecular Mechanisms and Clinical Applications,” Molecular Biomedicine 6 (2025): 152.

[212] A. Jain, A. Barge, and C. N. Parris, “Combination Strategies With PARP Inhibitors in BRCA-mutated Triple-negative Breast Cancer: Overcoming Resistance Mechanisms,” Oncogene 44 (2025): 193–207.

[213] A. Gonzalez-Gonzalez, Z. Guo, A. Meroni, et al., “Abstract P2-17-03: Preclinical Study of trastuzumab Deruxtecan (T-dxd; DS-8201a) in Combination With DNA Damage Response Pathway Inhibitors in HER2-low/Hormone Receptor Negative Breast Cancer Patient-derived Xenograft Models,” Cancer Research 83 (2023): P2-17-03.

[214] A. Bardia, S. Sun, N. Thimmiah, et al., “Antibody-drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients With Breast Cancer,” Clinical Cancer Research 30 (2024): 2917–2924.

[215] L. Stockmann, T.-J. Allen-Coyle, J. Crown, et al., “EV328/#856  synergistic Combination of sacituzumab govitecan and PARP Inhibitors Overcomes Olaparib Resistance in Ovarian Cancer Models,” International Journal of Gynecological Cancer 34 (2024): A253–A254.

[216] K. Tsuchikama, Y. Anami, S. Y. Y. Ha, et al., “Exploring the next Generation of Antibody-drug Conjugates,” Nature Reviews Clinical Oncology 21 (2024): 203–223.

[217] Y. Gu, Z. Wang, and Y. Wang, “Bispecific Antibody Drug Conjugates: Making 1+1>2,” Acta Pharmaceutica Sinica B 14 (2024): 1965–1986.

[218] H. Zeng, W. Ning, X. Liu, et al., “Unlocking the Potential of Bispecific ADCs for Targeted Cancer Therapy,” Frontiers in Medicine 18 (2024): 597–621.

[219] Q. Xue, J. Peng, W. Dai, et al., “A Biparatopic HER2-targeting ADC Constructed via Site-specific Glycan Conjugation Exhibits Superior Stability, Safety, and Efficacy,” RSC Chemical Biology 6 (2025): 1284–1296.

[220] N. E. Weisser, M. Sanches, E. Escobar-Cabrera, et al., “An Anti-HER2 Biparatopic Antibody That Induces Unique HER2 Clustering and Complement-dependent Cytotoxicity,” Nature Communications 14 (2023): 1394.

[221] R.-H. Xu, S. Wang, D. Ruan, et al., “Safety and Efficacy of TQB2102, a Novel Bispecific Anti-HER2 Antibody–drug Conjugate, in Patients With Advanced Solid Tumors: Preliminary Data From the First-in-human Phase 1 Trial,” Journal of Clinical Oncology 43 (2025): 3003–3003.

[222] L. Zhang, Y. Ma, Y. Zhao, et al., “BL-B01D1, a First-in-class EGFRxHER3 Bispecific Antibody-drug Conjugate (ADC), in Patients With Locally Advanced or Metastatic Solid Tumor: Results From a First-in-human Phase 1 Study,” Journal of Clinical Oncology 41 (2023): 3001–3001.

[223] J. Guan, X. Zhang, W. Wu, et al., “Abstract LB055: IBI3001: A Potentially First-in-class Site-specifically Conjugated B7-H3/EGFR Bispecific ADC for Multiple Solid Tumors,” Cancer Research 84 (2024): LB055.

[224] F. Comer, Y. Mazor, E. Hurt, et al., “Abstract 5736: AZD9592: An EGFR-cMET Bispecific Antibody-drug Conjugate (ADC) Targeting Key Oncogenic Drivers in Non-small-cell Lung Cancer (NSCLC) and Beyond,” Cancer Research 83 (2023): 5736.

[225] B. Zhang, J. Shi, X. Shi, et al., “Development and Evaluation of a human CD47/HER2 Bispecific Antibody for Trastuzumab-resistant Breast Cancer Immunotherapy,” Drug Resistance Updates 74 (2024): 101068.

[226] J. Tao, Y. Gu, W. Zhou, et al., “Dual-payload Antibody–drug Conjugates: Taking a Dual Shot,” European Journal of Medicinal Chemistry 281 (2025): 116995.

[227] M. Wen, A. Yu, Y. Park, et al., “Homogeneous Antibody-drug Conjugates With Dual Payloads: Potential, Methods and Considerations,” MAbs 17 (2025): 2498162.

[228] M. R. Levengood, X. Zhang, J. H. Hunter, et al., “Orthogonal Cysteine Protection Enables Homogeneous Multi-drug Antibody-drug Conjugates,” Angewandte Chemie 56 (2017): 733–737.

[229] N. Nilchan, X. Li, L. Pedzisa, et al., “Dual-mechanistic Antibody-drug Conjugate via Site-specific Selenocysteine/Cysteine Conjugation,” Antibody Therapeutics 2 (2019): 71–78.

[230] C. M. Yamazaki, A. Yamaguchi, Y. Anami, et al., “Antibody-drug Conjugates With Dual Payloads for Combating Breast Tumor Heterogeneity and Drug Resistance,” Nature Communications 12 (2021): 3528.

[231] Z. Miao, F. Lin, X. Rao, et al., “Phase 1 Study of ZV0203, a First in Class Pertuzumab ADC, in Patients With HER2 Positive Advanced Solid Tumors,” Journal of Clinical Oncology 42 (2024): e15004–e15004.

[232] S. E. Ackerman, C. I. Pearson, J. D. Gregorio, et al., “Immune-stimulating Antibody Conjugates Elicit Robust Myeloid Activation and Durable Antitumor Immunity,” Nature Cancer 2 (2021): 18–33.

[233] C. Fu, W. Tong, L. Yu, et al., “When Will the Immune-stimulating Antibody Conjugates (ISACs) be Transferred From Bench to Bedside?,” Pharmaceutical Research 203 (2024): 107160.

[234] H. Metz, M. Childs, J. Brevik, et al., “SBT6050, a HER2-directed TLR8 Therapeutic, as a Systemically Administered, Tumor-targeted human Myeloid Cell Agonist,” Journal of Clinical Oncology 38 (2020): 3110–3110.

[235] S. J. Klempner, M. Beeram, D. Sabanathan, et al., “209P interim Results of a Phase I/Ib Study of SBT6050 Monotherapy and Pembrolizumab Combination in Patients With Advanced HER2-expressing or Amplified Solid Tumors,” Annals of Oncology 32 (2021): S450.

[236] M. Yi, T. Li, Y. Gu, et al., “Triple Targeting of STING, TGF-β, and PD-L1 Boosts CXCL16–CXCR6 Signaling for Potent Antitumor Response,” Nature Communications 17 (2026): 1441.

[237] M. Li, X. Zhao, C. Yu, et al., “Antibody-drug Conjugate Overview: A state-of-the-art Manufacturing Process and Control Strategy,” Pharmaceutical Research 41 (2024): 419–440.

[238] H. He, X. Deng, Z. Wang, et al., “Recent Progress in the Development of Peptide-drug Conjugates (PDCs) for Cancer Therapy,” European Journal of Medicinal Chemistry 284 (2025): 117204.

[239] C. Fu, L. Yu, Y. Miao, et al., “Peptide-drug Conjugates (PDCs): A Novel Trend of Research and Development on Targeted Therapy, Hype or Hope?,” Acta Pharmaceutica Sinica B 13 (2023): 498–516.

[240] B. Zhang, M. Wang, L. Sun, et al., “Recent Advances in Targeted Cancer Therapy: Are PDCs the next Generation of ADCs?,” Journal of Medicinal Chemistry 67 (2024): 11469–11487.

[241] D. Wang, F. Yin, Z. Li, et al., “Current Progress and Remaining Challenges of Peptide–drug Conjugates (PDCs): Next Generation of Antibody-drug Conjugates (ADCs)?,” Journal of Nanobiotechnology 23 (2025): 305.

[242] P. Hoppenz, S. Els-Heindl, and A. G. Beck-Sickinger, “Peptide-drug Conjugates and Their Targets in Advanced Cancer Therapies,” Frontiers in Chemistry 8 (2020): 571.

[243] K. Parang, T. Do, C. Dinh, et al., “Tumor Targeting With Peptide-drug Conjugates: Showcasing Key Progress and Hurdles,” DDDT 20 (2026): 1–30.

[244] M. B. Hock, K. E. Thudium, M. Carrasco-Triguero, et al., “Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality,” The Aaps Journal [Electronic Resource] 17 (2015): 35–43.

[245] R. Tan, Z. Yang, J. Xie, et al., “Innovative Design Concepts in Tumor-targeting Peptide-drug Conjugates: Insights Into Emerging Applications,” Chinese Medical Journal 139 (2026): 222–232.

[246] A. Mousavizadeh, A. Jabbari, M. Akrami, et al., “Cell Targeting Peptides as Smart Ligands for Targeting of Therapeutic or Diagnostic Agents: A Systematic Review,” Colloids and Surfaces B: Biointerfaces 158 (2017): 507–517.

[247] R. O. Hynes, “Integrins: Bidirectional, Allosteric Signaling Machines,” Cell 110 (2002): 673–687.

[248] Y. Gu, B. Dong, X. He, et al., “The Challenges and Opportunities of αvβ3-based Therapeutics in Cancer: From Bench to Clinical Trials,” Pharmacological Research 189 (2023): 106694.

[249] M. Kanamori, S. R. V. Berg, G. Bergers, et al., “Integrin β3 Overexpression Suppresses Tumor Growth in a human Model of GliomagenesisImplications for the Role of β3 Overexpression in Glioblastoma Multiforme,” Cancer Research 64 (2004): 2751–2758.

[250] R. Huilcaman, A. Campos, P. Contreras, et al., “Inclusion of ΑVβ3 Integrin Into Extracellular Vesicles in a Caveolin-1 Tyrosine-14- phosphorylation Dependent Manner and Subsequent Transfer to Recipient Melanoma Cells Promotes Migration, Invasion and Metastasis,” Cell Communication and Signaling 23 (2025): 139.

[251] B. C. Casali, L. T. Gozzer, M. P. Baptista, et al., “The Effects of αvβ3 Integrin Blockage in Breast Tumor and Endothelial Cells Under Hypoxia in Vitro,” International Journal of Molecular Sciences 23 (2022): 1745.

[252] J. Hou, Y. Diao, W. Li, et al., “RGD Peptide Conjugation Results in Enhanced Antitumor Activity of PD0325901 Against Glioblastoma by both Tumor-targeting Delivery and Combination Therapy,” International Journal of Pharmaceutics 505 (2016): 329–340.

[253] M.-D. Wang, D.-Y. Hou, G.-T. Lv, et al., “Targeted in Situ Self-assembly Augments Peptide Drug Conjugate Cell-entry Efficiency,” Biomaterials 278 (2021): 121139.

[254] B. Wang, D. Tang, J. Cui, et al., “RGD-based Self-assembling Nanodrugs for Improved Tumor Therapy,” Frontiers in Pharmacology 15 (2024): 1477409.

[255] N. F. Brown, E. R. Murray, L. C. Cutmore, et al., “Integrin-αvβ6 Targeted Peptide-toxin Therapy in a Novel αvβ6-expressing Immunocompetent Model of Pancreatic Cancer,” Pancreatology 24 (2024): 445–455.

[256] E. R. Murray, N. F. Brown, P. Howard, et al., “Abstract 958: Effective Targeting of Pancreatic Ductal Adenocarcinoma Metastases With an Integrin αvβ6-targeting Peptide-drug Conjugate,” Cancer Research 81 (2021): 958.

[257] J. F. Deeken and W. Löscher, “The Blood-brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses,” Clinical Cancer Research 13 (2007): 1663–1674.

[258] A. Régina, M. Demeule, C. Ché, et al., “Antitumour Activity of ANG1005, a Conjugate Between paclitaxel and the New Brain Delivery Vector angiopep-2,” British Journal of Pharmacology 155 (2008): 185–197.

[259] P. Kumthekar, S.-C. Tang, A. J. Brenner, et al., “ANG1005, a Brain-penetrating Peptide-drug Conjugate, Shows Activity in Patients With Breast Cancer With Leptomeningeal Carcinomatosis and Recurrent Brain Metastases,” Clinical Cancer Research 26 (2020): 2789–2799.

[260] G. Guidotti, L. Brambilla, and D. Rossi, “Cell-penetrating Peptides: From Basic Research to Clinics,” Trends in Pharmacological Sciences 38 (2017): 406–424.

[261] D. Raucher and J. S. Ryu, “Cell-penetrating Peptides: Strategies for Anticancer Treatment,” Trends in Molecular Medicine 21 (2015): 560–570.

[262] M. Alas, A. Saghaeidehkordi, and K. Kaur, “Peptide-drug Conjugates With Different Linkers for Cancer Therapy,” Journal of Medicinal Chemistry 64 (2021): 216–232.

[263] R. Duncan, “Polymer Conjugates as Anticancer Nanomedicines,” Nature Reviews Cancer 6 (2006): 688–701.

[264] U. Hennrich and K. Kopka, “Lutathera: The First FDA- and EMA-approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy,” Pharmaceuticals (Basel) 12 (2019): 114.

[265] L. Du, C. Song, J. Du, et al., “Development of Sulfonium Tethered Peptides Conjugated With HDAC Inhibitor to Improve Selective Toxicity for Cancer Cells,” Bioorganic & Medicinal Chemistry 83 (2023): 117213.

[266] J. Shao, X. Lin, H. Wang, et al., “Targeted Degradation of Cell-surface Proteins via Chaperone-mediated Autophagy by Using Peptide-conjugated Antibodies,” Angewandte Chemie 63 (2024): e202319232.

[267] K. Ej, H. Ko, and B. Sn, “Peptide Spiders: Peptide-polymer Conjugates to Traffic Nucleic Acids,” Molecular Pharmaceutics 17 (2020): 3633–3642.

[268] J. R. Strosberg, M. E. Caplin, P. L. Kunz, et al., “177Lu-dotatate plus Long-acting Octreotide versus High-Dose Long-acting Octreotide in Patients With Midgut Neuroendocrine Tumours (NETTER-1): Final Overall Survival and Long-term Safety Results From an Open-label, Randomised, Controlled, Phase 3 Trial,” The Lancet Oncology 22 (2021): 1752–1763.

[269] S. Singh, D. Halperin, S. Myrehaug, et al., “[177Lu]lu-DOTA-TATE plus Long-acting Octreotide versus High-Dose Long-acting Octreotide for the Treatment of Newly Diagnosed, Advanced Grade 2–3, Well-differentiated, Gastroenteropancreatic Neuroendocrine Tumours (NETTER-2): An Open-label, Randomised, Phase 3 Study,” Lancet 403 (2024): 2807–2817.

[270] D. Chauhan, A. Ray, K. Viktorsson, et al., “In Vitro and in Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-flufenamide, Against Multiple Myeloma Cells,” Clinical Cancer Research 19 (2013): 3019–3031.

[271] P. G. Richardson, A. Oriol, A. Larocca, et al., “Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma,” Journal of Clinical Oncology 39 (2021): 757–767.

[272] S. Dhillon, “Melphalan Flufenamide (melflufen): First Approval,” Drugs 81 (2021): 963–969.

[273] F. H. Schjesvold, M.-A. Dimopoulos, S. Delimpasi, et al., “Melflufen or Pomalidomide plus Dexamethasone for Patients With Multiple Myeloma Refractory to Lenalidomide (OCEAN): A Randomised, Head-to-head, Open-label, Phase 3 Study,” The Lancet Haematology 9 (2022): e98–e110.

[274] U. Hennrich and M. Eder, “[177Lu]lu-PSMA-617 (PluvictoTM): The First FDA-approved Radiotherapeutical for Treatment of Prostate Cancer,” Pharmaceuticals 15 (2022): 1292.

[275] O. Sartor, J. de Bono, K. N. Chi, et al., “Lutetium-177-PSMA-617 for Metastatic Castration-resistant Prostate Cancer,” New England Journal of Medicine 385 (2021): 1091–1103.

[276] K. Fizazi, M. J. Morris, N. D. Shore, et al., “Health-related Quality of Life, Pain, and Symptomatic Skeletal Events With [177Lu]lu-PSMA-617 in Patients With Progressive Metastatic Castration-resistant Prostate Cancer (PSMAfore): An Open-label, Randomised, Phase 3 Trial,” The Lancet Oncology 26 (2025): 948–959.

[277] N. Li, J. Gong, J. Zhang, et al., “First-in-human, Phase I Study of CBP-1008, a First-in-class Bispecific Ligand Drug Conjugate (bi-XDC), in Patients With Advanced Solid Tumors,” Journal of Clinical Oncology 42 (2024): 5556–5556.

[278] K. Li, J. Wu, S. Ye, et al., “1830P CBP-1018, a bi-ligand-drug Conjugate Treated in Patients With Advanced Solid Tumors: A Phase I, Multi-center, Open-label, Dose-escalation and Dose Expansion Study,” Annals of Oncology 34 (2023): S991.

[279] G. Bennett, R. Lutz, P. Park, et al., “Abstract 1167: Development of BT1718, a Novel Bicycle Drug Conjugate for the Treatment of Lung Cancer,” Cancer Research 77 (2017): 1167.

[280] B. Bashir, J. S. Wang, G. Falchook, et al., “Results From First-in-human Phase I Dose-escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors,” Journal of Clinical Oncology 42 (2024): 3443–3452.

[281] A. Cigliola, V. Tateo, M. Ravasi, et al., “Zelenectide Pevedotin (BT-8009): A Bicyclic Peptide Toxin Conjugate Targeting Nectin-4 for the Treatment of Bladder Cancer,” Expert Opinion on Investigational Drugs 34 (2025): 371–378.

[282] M. Demeule, C. Charfi, J.-C. Currie, et al., “TH1902, a New Docetaxel-peptide Conjugate for the Treatment of Sortilin-positive Triple-negative Breast Cancer,” Cancer Science 112 (2021): 4317–4334.

[283] I. I. Rodriguez Rivera, N. Hafez, A. W. Tolcher, et al., “CBX-12-101: A First-in-human Study of CBX-12, an Alphalex Peptide Drug Conjugate (PDC) in Patients (pts) With Advanced or Metastatic Solid Tumors,” Journal of Clinical Oncology 41 (2023): 3087–3087.

[284] F. Meyer-Losic, C. Nicolazzi, J. Quinonero, et al., “DTS-108, a Novel Peptidic Prodrug of SN38: In Vivo Efficacy and Toxicokinetic Studies,” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 14 (2008): 2145–2153.

[285] C. J. Twelves, U. Banerji, W. D. Tap, et al., “646P a Phase I Trial of AVA6000, a Fibroblast Activation Protein (FAP)-released, Tumor Microenvironment (TME)-targeted Doxorubicin Peptide Drug Conjugate in Patients With FAP-positive Solid Tumors,” Annals of Oncology 35 (2024): S511.

[286] J. Li, X. Yao, H. Wang, et al., “963P SC-101, a Nectin-4-targeting Peptide-drug Conjugate (PDC), in Patients (pts) With Advanced or Metastatic Solid Tumors: Results From Dose Escalation Study,” Annals of Oncology 36 (2025): S590–S591.

[287] Y.-Q. Huang, J.-D. Yuan, H.-F. Ding, et al., “Design, Synthesis and Pharmacological Evaluation of a Novel PEG-cRGD-conjugated Irinotecan Derivative as Potential Antitumor Agent,” European Journal of Medicinal Chemistry 158 (2018): 82–90.

[288] D. S. Miller, G. Scambia, I. Bondarenko, et al., “ZoptEC: Phase III Randomized Controlled Study Comparing zoptarelin With doxorubicin as Second Line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer (NCT01767155),” Journal of Clinical Oncology 36 (2018): 5503–5503.

[289] S. G. T. Pereira, S. Hudoklin, M. E. Kreft, et al., “Intracellular Activation of a Prostate Specific Antigen-cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-nanomedicine Design,” Molecular Pharmaceutics 16 (2019): 1573–1585.

[290] B. H. White, K. Whalen, K. Kriksciukaite, et al., “Discovery of an SSTR2-targeting Maytansinoid Conjugate (PEN-221) With Potent Activity in Vitro and in Vivo,” Journal of Medicinal Chemistry 62 (2019): 2708–2719.

[291] D. Mahalingam, J. Peguero, P. Cen, et al., “A Phase II, Multicenter, Single-arm Study of mipsagargin (G-202) as a Second-line Therapy Following sorafenib for Adult Patients With Progressive Advanced Hepatocellular Carcinoma,” Cancers (Basel) 11 (2019): 833.

[292] V. P. Chavda, H. K. Solanki, M. Davidson, et al., “Peptide-drug Conjugates: A New Hope for Cancer Management,” Molecules 27 (2022): 7232.

[293] K. K. Curtis, J. Sarantopoulos, D. W. Northfelt, et al., “Novel LHRH-receptor-targeted Cytolytic Peptide, EP-100: First-in-human Phase I Study in Patients With Advanced LHRH-receptor-expressing Solid Tumors,” Cancer Chemotherapy and Pharmacology 73 (2014): 931–941.

[294] A. Chelariu-Raicu, A. Nick, R. Urban, et al., “A Multicenter Open-label Randomized Phase II Trial of paclitaxel plus EP-100, a Novel LHRH Receptor-targeted, Membrane-disrupting Peptide, versus paclitaxel Alone for Refractory or Recurrent Ovarian Cancer,” Gynecologic Oncology 160 (2021): 418–426.

[295] M. Wang, J. Liu, M. Xia, et al., “Peptide-drug Conjugates: A New Paradigm for Targeted Cancer Therapy,” European Journal of Medicinal Chemistry 265 (2024): 116119.

[296] K. Kalimuthu, B.-C. Lubin, A. Bazylevich, et al., “Gold Nanoparticles Stabilize Peptide-drug-conjugates for Sustained Targeted Drug Delivery to Cancer Cells,” J Nanobiotechnology 16 (2018): 34.

[297] J. Deng, J. Shi, D. Li, et al., “Cancer-targeting Drug Conjugates Drives a New Era in Precise Cancer Treatment,” Chinese Chemical Letters 37 (2026): 110960.

[298] L. Moumné, A.-C. Marie, and N. Crouvezier, “Oligonucleotide Therapeutics: From Discovery and Development to Patentability,” Pharmaceutics 14 (2022): 260.

[299] X. Chi, P. Gatti, and T. Papoian, “Safety of Antisense Oligonucleotide and siRNA-based Therapeutics,” Drug Discovery Today 22 (2017): 823–833.

[300] J. Dugal-Tessier, S. Thirumalairajan, and N. Jain, “Antibody-oligonucleotide Conjugates: A Twist to Antibody-drug Conjugates,” Journal of Clinical Medicine 10 (2021): 838.

[301] J. Banerjee and M. Nilsen-Hamilton, “Aptamers: Multifunctional Molecules for Biomedical Research,” Journal of Molecular Medicine (Berlin) 91 (2013): 1333–1342.

[302] A. D. Keefe, S. Pai, and A. Ellington, “Aptamers as Therapeutics,” Nature Reviews Drug Discovery 9 (2010): 537–550.

[303] G. Zhu and X. Chen, “Aptamer-based Targeted Therapy,” Advanced Drug Delivery Reviews 134 (2018): 65–78.

[304] Y.-F. Huang, D. Shangguan, H. Liu, et al., “Molecular Assembly of an Aptamer-drug Conjugate for Targeted Drug Delivery to Tumor Cells,” Chembiochem 10 (2009): 862–868.

[305] F. Xu, J. Xu, F. Han, et al., “Novel Aptamer-drug Conjugate for Targeted Therapy in Triple-negative Breast Cancer,” Journal of Medicinal Chemistry 68 (2025): 19971–19983.

[306] W. Ma, Y. Yang, Z. Liu, et al., “Self-assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-positive Gastric Cancer,” ACS Applied Materials & Interfaces 15 (2023): 43359–43373.

[307] X. Zheng, Y. Wang, H. Duan, et al., “A New NCL-targeting Aptamer-drug Conjugate as a Promising Therapy Against Esophageal Cancer,” Journal of Nanobiotechnology i 23 (2025): 52.

[308] L. Xing, L. Lv, J. Ren, et al., “Advances in Targeted Therapy for Pancreatic Cancer,” Biomedicine & Pharmacotherapy 168 (2023): 115717.

[309] M. Su, Y. Liu, H. Lin, et al., “An Aptamer-drug Conjugate for Promising Cancer Therapy With Comprehensive Evaluation From Rodents to Non-human Primates,” Signal Transduction and Targeted Therapy 10 (2025): 316.

[310] G. Casi and D. Neri, “Antibody–drug Conjugates and Small Molecule–drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents,” Journal of Medicinal Chemistry 58 (2015): 8751–8761.

[311] J. Zhu, Y. Xiong, X. Bai, et al., “Small Molecule-drug Conjugates: Mechanistic Insights and Strategic Design for Enhanced Cancer Therapy,” Chinese Chemical Letters 36 (2025): 110799.

[312] C. Li, K. Shi, S. Zhao, et al., “Natural-source Payloads Used in the Conjugated Drugs Architecture for Cancer Therapy: Recent Advances and Future Directions,” Pharmacological Research 207 (2024): 107341.

[313] S. S. Panikar, N. Banu, J. Haramati, et al., “Nanobodies as Efficient Drug-carriers: Progress and Trends in Chemotherapy,” Journal of Controlled Release 334 (2021): 389–412.

[314] S. Yu, L. Zhang, A. Wang, et al., “Nanobodies: The Potential Application in Bacterial Treatment and Diagnosis,” Biochemical Pharmacology 214 (2023): 115640.

[315] S. Steeland, R. E. Vandenbroucke, and C. Libert, “Nanobodies as Therapeutics: Big Opportunities for Small Antibodies,” Drug Discovery Today 21 (2016): 1076–1113.

[316] T. Fang, J. N. Duarte, J. Ling, et al., “Structurally Defined αMHC-II Nanobody-drug Conjugates: A Therapeutic and Imaging System for B-cell Lymphoma,” Angewandte Chemie 55 (2016): 2416–2420.

[317] Y. Wu, M. Zhu, B. Sun, et al., “A Humanized Trivalent Nectin-4-targeting Nanobody Drug Conjugate Displays Potent Antitumor Activity in Gastric Cancer,” Journal of Nanobiotechnology 22 (2024): 256.

[318] X. Yu, Y. Long, B. Chen, et al., “PD-L1/TLR7 Dual-targeting Nanobody-drug Conjugate Mediates Potent Tumor Regression via Elevating Tumor Immunogenicity in a Host-expressed PD-L1 Bias-dependent Way,” Journal for ImmunoTherapy of Cancer 10 (2022): e004590.

[319] P. S. Dragovich, “Degrader-antibody Conjugates,” Chemical Society Reviews 51 (2022): 3886–3897.

[320] Y. B. Poudel, R. R. Thakore, and E. P. Chekler, “The New Frontier: Merging Molecular Glue Degrader and Antibody-drug Conjugate Modalities to Overcome Strategic Challenges,” Journal of Medicinal Chemistry 67 (2024): 15996–16001.

[321] Y. Tao, Y. Lu, B. Yu, et al., “Molecular Glue Meets Antibody: Next-generation Antibody-drug Conjugates,” Trends in Pharmacological Sciences 46 (2025): 520–534.

[322] T. H. Pillow, P. Adhikari, R. A. Blake, et al., “Antibody Conjugation of a Chimeric BET Degrader Enables in Vivo Activity,” Chemmedchem 15 (2020): 17–25.

[323] P. S. Dragovich, P. Adhikari, R. A. Blake, et al., “Antibody-mediated Delivery of Chimeric Protein Degraders Which Target Estrogen Receptor Alpha (ERα),” Bioorganic & Medicinal Chemistry Letters 30 (2020): 126907.

[324] L. Wang, Y. Ke, Q. He, et al., “A Novel ROR1-targeting Antibody-PROTAC Conjugate Promotes BRD4 Degradation for Solid Tumor Treatment,” Theranostics 15 (2025): 1238–1254.

[325] L. Xijing and B. Cheng, “Recent Advances in Radionuclide Drug Conjugates (RDCs) for Cancer Theranostics: From Targeted Design to Clinical Translation,” Bioorganic Chemistry 167 (2025): 109240.

[326] S. V. Gudkov, N. Y. Shilyagina, V. A. Vodeneev, et al., “Targeted Radionuclide Therapy of human Tumors,” International Journal of Molecular Sciences 17 (2015): 33.

[327] M. Xu, J. Chen, P. Zhang, et al., “An Antibody-radionuclide Conjugate Targets Fibroblast Activation Protein for Cancer Therapy,” European Journal of Nuclear Medicine and Molecular Imaging 50 (2023): 3214–3224.

[328] X. Lu, Y. Zhu, X. Deng, et al., “Development of a Supermolecular Radionuclide-drug Conjugate System for Integrated Radiotheranostics for Non-small Cell Lung Cancer,” Journal of Medicinal Chemistry 67 (2024): 11152–11167.

[329] A. Galbiati, M. Bocci, D. Ravazza, et al., “Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-targeted Radiopharmaceutical Therapeutic for Solid Tumors,” Journal of Nuclear Medicine 65 (2024): 1604–1610.

[330] S. C. Hsiao, B. J. Shum, H. Onoe, et al., “Direct Cell Surface Modification With DNA for the Capture of Primary Cells and the Investigation of Myotube Formation on Defined Patterns,” Langmuir 25 (2009): 6985–6991.

[331] X. Ma, J. Jiang, X. An, et al., “Advances in Research Based on Antibody-cell Conjugation,” Frontiers in Immunology 14 (2023): 1310130.

[332] T. J. Laskowski, A. Biederstädt, and K. Rezvani, “Natural Killer Cells in Antitumour Adoptive Cell Immunotherapy,” Nature Reviews Cancer 22 (2022): 557–575.

[333] H.-K. Li, C.-W. Hsiao, S.-H. Yang, et al., “A Novel off-the-shelf Trastuzumab-armed NK Cell Therapy (ACE1702) Using Antibody-cell-conjugation Technology,” Cancers (Basel) 13 (2021): 2724.

[334] F. G. Sevari, A. Mehdizadeh, K. Abbasi, et al., “Cytokine-induced Killer Cells: New Insights for Therapy of Hematologic Malignancies,” Stem Cell Research & Therapy 15 (2024): 254.

[335] M. J. Frank, N. Olsson, A. Huang, et al., “A Novel Antibody-cell Conjugation Method to Enhance and Characterize Cytokine-induced Killer Cells,” Cytotherapy 22 (2020): 135–143.

[336] H.-K. Li, T.-S. Wu, Y. Ru, et al., “Allogeneic Cetuximab-armed Gamma Delta T Cells Using Antibody-cell Conjugation Technology for the Treatment of EGFR-expressing Solid Tumors,” Journal for ImmunoTherapy of Cancer 13 (2025): e010500.

[337] V. P. Chavda, P. C. Balar, D. Teli, et al., “Antibody-biopolymer Conjugates in Oncology: A Review,” Molecules 28 (2023): 2605.

[338] D. Liu, “Progress and Prospect of Antibody-biopolymer Conjugates in Disease Therapy,” Biomedical Data Science 5 (2025): 119–122.

[339] M. Sreeranganathan, S. Uthaman, B. Sarmento, et al., “In Vivo Evaluation of Cetuximab-conjugated Poly(γ-glutamic acid)-docetaxel Nanomedicines in EGFR-overexpressing Gastric Cancer Xenografts,” International Journal of Nanomedicine 12 (2017): 7165–7182.

[340] A. M. Zahedi, M. Pirouzbakht, S. Zanganeh, et al., “Aptamer-drug Conjugates (ApDCs): Transformative Approaches in Targeted Cancer Therapy and Precision Oncology,” International Journal of Pharmaceutics 681 (2025): 125902.

[341] S. Banerjee, A. Mariya, S. Vangapally, et al., “Nanobody-drug Conjugates as Versatile Tools for Improving Therapeutic Potential,” Biochemical Engineering Journal 228 (2026): 110072.

[342] O. J. Okpasuo, O. T. Olaoba, P. Bokolo, et al., “The Evolving Landscape of Antibody-based Cancer Therapies: From Monospecific to Multi-specific and Beyond,” Critical Reviews in Oncology/Hematology 217 (2026): 105037.

[343] B. Chen, X. Zheng, J. Wu, et al., “Antibody–drug Conjugates in Cancer Therapy: Current Landscape, Challenges, and Future Directions,” Molecular Cancer 24 (2025): 279.

[344] H. N. Tan, M. A. Morcillo, J. Lopez, et al., “Treatment-related Adverse Events of Antibody Drug-conjugates in Clinical Trials,” Journal of Hematology & Oncology 18 (2025): 71.

[345] T. D. Nguyen, B. M. Bordeau, and J. P. Balthasar, “Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability,” Cancers (Basel) 15 (2023): 713.

[346] M. E. Lacouture, A. B. Patel, J. E. Rosenberg, et al., “Management of Dermatologic Events Associated with the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin,” The Oncologist 27 (2022): e223–e232.

[347] S. Li, X. Zhao, K. Fu, et al., “Resistance to Antibody-drug Conjugates: A Review,” Acta Pharmaceutica Sinica B 15 (2025): 737–756.

[348] K. Zhou, X. Liu, and H. Zhu, “Overcoming Resistance to Antibody-drug Conjugates: From Mechanistic Insights to Cutting-edge Strategies,” Journal of Hematology & Oncology 18 (2025): 96.

[349] A. Armstrong, F. Coburn, Y. Nsereko, et al., “Peptide-drug Conjugates: A New Hope for Cancer,” Journal of Peptide Science 31 (2025): e70040.

[350] S. Chuprakov, A. O. Ogunkoya, R. M. Barfield, et al., “Tandem-cleavage Linkers Improve the in Vivo Stability and Tolerability of Antibody-drug Conjugates,” Bioconjugate Chem 32 (2021): 746–754.

[351] H.-P. Yao, H. Zhao, R. Hudson, et al., “Duocarmycin-based Antibody-drug Conjugates as an Emerging Biotherapeutic Entity for Targeted Cancer Therapy: Pharmaceutical Strategy and Clinical Progress,” Drug Discovery Today 26 (2021): 1857–1874.

[352] A. Pahl, C. Lutz, and T. Hechler, “Amanitins and Their Development as a Payload for Antibody-drug Conjugates,” Drug Discovery Today: Technologies 30 (2018): 85–89.

[353] B. A. Lipert, K. N. Siemens, A. Khan, et al., “CRISPR Screens With Trastuzumab Emtansine in HER2-positive Breast Cancer Cell Lines Reveal New Insights Into Drug Resistance,” Breast Cancer Research 27 (2025): 48.

[354] F. Buttgereit, J. Aelion, B. Rojkovich, et al., “Efficacy and Safety of ABBV-3373, a Novel Anti-tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-drug Conjugate, in Adults With Moderate-to-severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-blind, Active-controlled Proof-of-concept Phase IIa Trial,” Arthritis & Rheumatology 75 (2023): 879–889.

[355] A. Tafazzol, S. Cruz-González, X. Shi, et al., “Abstract 7857: Multi-modal Real-world Data Uncovers Predictors of Clinical Response to TOP1i and Optimizes ADC Strategies in Colorectal Cancer,” Cancer Research 86 (2026): 7857.

[356] B. Esapa, Y. Liu, A. M. Chenoweth, et al., “An Antibody-drug Conjugate Designed Through Clone and Isotype Selection Restricts the Growth of CSPG4-expressing Triple-negative Breast Cancer,” npj Precision Oncology 10 (2026): 161.

[357] Q. Wei, P. Li, T. Yang, et al., “The Promise and Challenges of Combination Therapies With Antibody-drug Conjugates in Solid Tumors,” Journal of Hematology & Oncology 17 (2024): 1.

[358] T. D. Nguyen, B. M. Bordeau, and J. P. Balthasar, “Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-antibody-drug Conjugates,” Molecular Cancer Therapeutics 22 (2023): 1332–1342.

[359] B. M. Bordeau, T. D. Nguyen, J. R. Polli, et al., “Payload-binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-drug Conjugates,” Molecular Cancer Therapeutics 22 (2023): 459–470.

[360] D. E. Zhang, T. He, T. Shi, et al., “Trends in the Research and Development of Peptide Drug Conjugates: Artificial Intelligence Aided Design,” Frontiers in Pharmacology 16 (2025): 1553853.

[361] Y. E. Jang, M. Kwon, C. W. Kwon, et al., “Integrative Peptide Drug Development: Chemical Engineering, AI-driven Design, and Cell-penetrating Peptides,” Pharmaceutics 18 (2026): 537.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.